Proteases and interleukin-6 gene analysis in 92 giant cell tumors of bone

Annals of Oncology

Volumn 15, Issue 3, 2004, Pages 498-503

  Gamberi, G ^a   Benassi, M S ^a   Ragazzini, P ^a   Pazzaglia, L ^a   Ponticelli, F ^a   Ferrari, C ^a   Balladelli, A ^a   Mercuri, M ^a   Gigli, M ^a   Bertoni, F ^a   Picci, P ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

Giant cell tumor; Interleukin 6; Proteases

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 6; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEINASE; UROKINASE; UROKINASE RECEPTOR;

ARTICLE; BONE TUMOR; CONTROLLED STUDY; CYTOKINE RELEASE; DEGRADATION; DISEASE ACTIVITY; EXTRACELLULAR MATRIX; GENE AMPLIFICATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GIANT CELL TUMOR; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; MAJOR CLINICAL STUDY; OSTEOLYSIS; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL; TUMOR RECURRENCE;

BONE NEOPLASMS; BONE RESORPTION; GIANT CELL TUMOR OF BONE; HUMANS; IMMUNOENZYME TECHNIQUES; INTERLEUKIN-6; NEOPLASM PROTEINS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; RECEPTORS, CELL SURFACE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL; URINARY PLASMINOGEN ACTIVATOR;

EID: 11144355953     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh091     Document Type: Article

References (35)

1. Campanacci M. Giant cell tumor of bone. Curr Orthop 1993; 7: 26-35.
2. Jaffe H, Lichtenstein L, Portis R. Giant cell tumor of bone. Its pathologic appearance, grading, supposed variants and treatment. Arch Pathol 1940; 30: 993-1031.
3. Goldring G, Roelke M, Petrison K et al. Human giant cell tumor of bone: Identification and characterisation of cell types. J Clin Invest 1987; 79: 483-491.
4. Katz E, Nyska M, Okon E et al. Growth rate analysis of lung metastases from histologically benign giant cell tumours of bone. Cancer 1987; 59: 1831-1836.
5. Ladanyi M, Tragano F, Huvos A. Benign metastasizing giant cell tumours of bone. Cancer 1989; 64: 1521-1526.
6. Pollanen J, Saksela O, Salonen E et al. Distinct localisations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells. J Cell Biol 1987; 104: 1085-1096.
7. Kwaan H. The plasminogen-plasmin system in malignancy. Cancer Met Rev 1992; 11: 291-311.
8. Luqmani Y, Temmim L, Parkar A et al. Clinical implications of urokinase and tissue type plasminogen activators and their inhibitor (PAI-1) in breast cancer tissue. Oncol Rep 2002; 9: 645-651.
9. Sten-Linder M, Seddighzadeh M, Engel G et al. Prognostic importance of the u-PA/PAI-1 complex in breast cancer. Anticancer Res 2001; 21: 2861-2865.
10. Look M, van Putten W, Duffy M et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI1 in 8377 breast cancer patients. J Natl Cancer Inst 2002; 94: 116-128.
11. Pedersen H, Brunner N, Francis D et al. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 1994; 54: 4671-4675.
12. Seetoo D, Crowe P, Russell P et al. Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer. J Surg Oncol 2003; 82: 184-193.
13. Loktionov A, Watson M, Stebbings W et al. Plasminogen activator inhibitor-1 gene polymorphism and colorectal cancer risk and prognosis. Cancer Lett 2003; 189: 189-196.
14. Papadopoulou S, Scorilas A, Yotis J et al. Significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 (PAI-1) expression in human colorectal carcinomas. Tumor Biol 2002; 23: 170-178.
15. Konecny G, Untch M, Pihan A et al. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer. Clin Cancer Res 2001; 7: 1743-1749.
16. Taponeco F, Curcio C, Giuntini A et al. Expression and prognostic significance of urokinase and plasminogen activator inhibitor type-1 in endometrial hyperplasia and cancer. J Exp Clin Cancer Res 2001; 20: 239-246.
17. Memarzedeh S, Kozak K, Chang L et al. Urokinase plasminogen activator receptor: Prognostic biomarker for endometrial cancer. Proc Natl Acad Sci USA 2002; 99: 10647-10652.
18. Nekarda H, Siewert J, Schmitt M et al. Tumor-associated proteolytic factors uPA and PAI1 and survival in totally resected gastric cancer. Lancet 1994; 343: 117.
19. Campanacci M, Bagnara G, Serra M et al. Giant cell tumor of bone: A model for the in vitro human osteoclast characterization. Tumori 1989; 75: 389-395.
20. Komiya S, Sasaguri Y, Inoue A et al. Characterization of cells cultured from human giant-cell tumors of bone. Clin Orthop 1990; 258: 304-309.
21. Ohsaki Y, Takahashi S, Scarcez T et al. Evidence for an autocrine/paracrine role for interleukin-6 in bone resoption by giant cell tumor of bone. Endocrinology 1992; 131: 2229-2234.
22. Grano M, Colucci S, Portoghese A et al. New model for bone resorption study in vitro: Human osteoclast-like cells from giant cell tumors of bone. J Bone Min Res 1994; 7: 1013-1020.
23. Giovannini M, Strippoli P, Serra M et al. Production of interleukin-6 by human osteoclast-like cells from giant cell tumor of bone. Int J Oncol 1996; 8: 297-303.
24. Gamberi G, Serra M. Ragazzini P et al. Identification of markers of possible prognostic value in 57 giant cell tumors of bone. Oncol Rep 2003; 10: 351-356.
25. Campanacci M. Bone and Soft Tissue Tumors. Wien: Springer-Verlag; 1999.
26. Orlando C, Pinzani P, Pazzagli M. Developments in quantitative PCR. Clin Chem Lab Med 1998; 36: 255-269.
27. Lehmann U, Glockner S, Kleeberger W et al. Detection of gene amplification in archivial breast cancer specimens by laser assisted microdissection and quantitative real time polymerase chain reaction. Am J Pathol 2000; 156: 1855-1864.
28. Wright DH, Manos MM. Sample preparation from paraffin-Ambedded tissues. In: Innis M (ed.): PCR Protocols: a Guide to Methods and Application. Emeryville, CA: Academic Press 1990; 153-158.
29. Lakowicz Joseph R. Energy Transfer. Principles of Fluorescent Spectroscopy. New York: Plenum Press 1983; 303-339.
30. Athanasou N, Bliss E, Gatter K et al. An immunohistological study of giant cell tumor of bone: Evidence for an osteoclast origin of the giant cells. J Pathol 1985; 147: 153-158.
31. Bertoni F, Present D, Enneking WF. Giant-cell tumor of bone with pulmonary metastases. J Bone Joint Surg Am 1985; 67: 890-900.
32. Kohn E, Liotta L. Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res 1995; 55: 1856-1862.
33. Andreasen P, Kjoller L, Christensen L et al. The urochinase-type plasminogen activator system in cancer metastasis: A review. Int J Cancer 1997; 72: 1-22.
34. Ishimi Y, Miyaura C, Jin C et al. IL-6 is produced by osteoblasts and induces bone resorption. J Immunol 1990; 145: 3297-3303.
35. Littlewood A, Russel J, Harvey G et al. The modulation of exspression of IL-6 and its receptor in human osteoblasts in vitro. Endocrinology 1991; 129: 1513-1520.